The multiplicity of action of cannabinoids: Implications for treating neurodegeneration

CNS Neuroscience and Therapeutics

Volumn 17, Issue 6, 2011, Pages 637-644

  Gowran, Aoife ^a   Noonan, Janis ^a   Campbell, Veronica A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Alzheimer's disease; Cannabinoid; Cerebral ischemia; Multiple sclerosis; Neurodegeneration; Parkinson's disease

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DELTA8 TETRAHYDROCANNABINOL; DEXANABINOL; DRONABINOL; G PROTEIN COUPLED RECEPTOR; LIGAND; N (3 FURYLMETHYL)ARACHIDONAMIDE; RIMONABANT;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; APPETITE; BRAIN INFARCTION; BRAIN ISCHEMIA; CELL FATE; CELL SURVIVAL; CHEMICAL STRUCTURE; COGNITION; COGNITIVE DEFECT; DRUG MECHANISM; DRUG TARGETING; EXCITOTOXICITY; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PAIN; PARKINSON DISEASE; RECEPTOR DENSITY; REVIEW;

AGED; ALZHEIMER DISEASE; BRAIN ISCHEMIA; CANNABINOIDS; HUMANS; HUNTINGTON DISEASE; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID;

EID: 79952536002     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00195.x     Document Type: Review

References (134)

1. O'Shaugnessey WB. On the preparation of the Indian hemp, or Gunjah (Cannabis Indica) and their effects on the animal system in health and their utility in the treatment of tetanus and other convulsive disorders. Trans Med Phys Soc Calcutta 1842;8:421-461.
2. Mechoulam R, Gaoni Y. A total synthesis of Dl-Delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 1965;87:3273-3275.
3. Sagar DR, Gaw AG, Okine BR, Woodhams SG, Wong A, Kendall DA, Chapman V. Dynamic regulation of the endocannabinoid system: Implications for analgesia. Mol Pain 2009;5:59.
4. Butler RK, Rea K, Lang Y, Gavin AM, Finn DP. Endocannabinoid-mediated enhancement of fear-conditioned analgesia in rats: Opioid receptor dependency and molecular correlates. Pain 2008;140:491-500.
5. Jesudason D, Wittert G. Endocannabinoid system in food intake and metabolic regulation. Curr Opin Lipidol 2008;19:344-348.
6. Stoving RK, Andries A, Brixen K, Flyvbjerg A, Horder K, Frystyk J. Leptin, ghrelin, and endocannabinoids: Potential therapeutic targets in anorexia nervosa. J Psychiatr Res 2009;43:671-679.
7. Dowie MJ, Bradshaw HB, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience 2009;163:456-465.
8. Fernandez-Ruiz J, Lastres-Becker I, Cabranes A, Gonzalez S, Ramos JA. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids 2002;66:257-267.
9. Heifets BD, Castillo PE. Endocannabinoid signaling and long-term synaptic plasticity. Ann Rev Physiol 2009;71:283-306.
10. Marchalant Y, Brothers HM, Norman GJ, Karelina K, DeVries AC, Wenk GL. Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis. Neurobiol Dis 2009;34:300-307.
11. Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J 2009;11:109-119.
12. Campbell VA, Gowran A. Alzheimer's disease: Taking the edge off with cannabinoids? Br J Pharmacol 2007;152:655-662.
13. Guzman M, Sanchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacol Ther 2002;95:175-184.
14. Guzman M. Neurons on cannabinoids: Dead or alive? Br J Pharmacol 2003;140:439-440.
15. Turcott D, Le Dorze J-A, Esfahani F, Frost E, Gomori A, Namaka M. Examining the roles of cannabinoids in pain and other therapeutic indications: A review. Exp Opinion 2010;11:17-31.
16. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-441.
17. 9-tetrahydrocannabinol in patients with recurrent glioblasoma multiforme. Br J Cancer 2006;95:197-203.
18. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 1991;11:563-583.
19. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005;310:329-332.
20. Nunez E, Benito C, Tolon RM, Hillard CJ, Griffin WS, Romero J. Glial expression of cannabinoid CB2 receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience 2008;151:104-110.
21. Thakur GA, Tichkule R, Bajaj S, Makriyannis A. Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat 2009;19:1647-1673.
22. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 2007;152:567-575.
23. Sharir H, Abood ME. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 2010;126:301-313.
24. Nevalainen T, Irving AJ. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? Curr Top Med Chem 2010;10:799-813.
25. McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM, Bradshaw HB. N-arachidononyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 2010;11:44.
26. Costa B, Bettoni I, Petrosino S, Comelli F, Giagnoni G, Di Marzo V. The dual fatty acid amide hydrolase/TRPV1 blocker, arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharmacol Res 2010;61:537-546.
27. Miyamoto N, Tanaka R, Zhang N, et al. Crucial role for Ser133-phosphorylated form of cyclic AMP-responsive element binding protein signaling in the differentiation and survival of neural progenitors under chronic cerebral hypoperfusion. Neuroscience 2009;162:525-536.
28. Hampson RE, Mu J, Deadwyler SA. Cannabinoid and kappa opioid receptors reduce potassium K+ current via activation of G(s) proteins in cultured hippocampal neurons. J Neurophysiol 2000;84:2356-2364.
29. Mackie K, Devane WA, Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 1993;44:498-503.
30. Deadwyler SA, Hampson RE, Mu J, Whyte A, Childers S. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther 1995;273:734-743.
31. Nicholson RA, Liao C, Zheng J, et al. Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Res 2003;978:194-204.
32. Hillard CJ. Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr Pharm Des 2008;14:2347-2361.
33. Minati L, Edginton T, Bruzzone MG, Giaccone G. Current concepts in Alzheimer's disease: A multidisciplinary review. Am J Alzheimers Dis Other Demen 2009;24:95-121.
34. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999;271:126-128.
35. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007;184:69-91.
36. Pratico D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: Lights and shadows. Ann N Y Acad Sci 2008;1147:70-78.
37. Riedel G, Davies SN. Cannabinoid function in learning, memory and plasticity. Handb Exp Pharmacol 2005;168:445-477.
38. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci 2005;25:1904-1913.
39. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 1994;63:637-652.
40. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, Romero J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 2003;23:11136-11141.
41. Van Der Stelt M, Mazzola C, Esposito G, et al. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 2006;63:1410-1424.
42. 2+ influx through the N-methyl-D-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211. Brain Res 1993;622:79-85.
43. Eshhar N, Striem S, Biegon A. HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport 1993;5:237-240.
44. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003;302:84-88.
45. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992;89:3825-3829.
46. Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997;78:43-50.
47. 2+ channel current. Am J Physiol 1999;276(6 Pt 2):H2085-H2093.
48. Zhuang SY, Bridges D, Grigorenko E, McCloud S, Boon A, Hampson RE, Deadwyler SA. Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology 2005;48:1086-1096.
49. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, Lutz B. Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 2004;19:1691-1698.
50. Scharfman H, Goodman J, Macleod A, Phani S, Antonelli C, Croll S. Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Exp Neurol 2005;192:348-356.
51. Peng S, Garzon DJ, Marchese M, et al. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci 2009;29:9321-9329.
52. Lee J, Fukumoto H, Orne J, et al. Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Exp Neurol 2005;194:91-96.
53. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
54. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995;45:1441-1445.
55. 2 suppresses microglial activation. J Neuroinflamm 2005;12:22-29.
56. Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Ribson RM, Rothwell NJ. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 2003;23:6470-6474.
57. Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ, Janda KD. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 2006;3:773-777.
58. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998;95:8268-8273.
59. Esposito G, Scuderi C, Savani C, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1ß and iNOS expression. Br J Pharmacol 2007;151:1272-1279.
60. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on ß-amyloid-induced toxicity in PC12 cells. J Neurochem 2004;89:134-141.
61. Esposito G, De Filippis D, Carnuccio R, Izzo AG, Iuvone T. The marijuana component, cannabidiol, inhibits ß-amyloid-induced tau protein hyperphosphorylation through Wnt/ß-catenin pathway rescue in PC12 cells. J Mol Med 2006;84:253-258.
62. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:913-919.
63. 9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 2006;185:524-528.
64. Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev 2009;CD007204. doi:. CD007204.pub2.
65. Buntinx M, Stinissen P, Steels P, Ameloot M, Raus J. Immune-mediated oligodendrocyte injury in multiple sclerosis: Molecular mechanisms and therapeutic interventions. Crit Rev Immunol 2002;22:391-424.
66. Vercellino M, Merola A, Piacentino C, et al. Altered glutamate reuptake in relapsing-remitting secondary progressive multiple sclerosis cortex: Correleation with microglia infiltration, demyelination and neuronal and synaptic damage. J Neuropathol Exp Neurol 2007;66:732-739.
67. Docagne F, Muneton V, Clemente D, et al. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol Cell Neurosci 2007;34:551-561.
68. Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: A systematic review. BMC Neurol 2009;9:59.
69. 9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clin Ther 2007;29:2068-2079.
70. Zajicek J, Fox P, Sanders H, Wright DE, Vickery PJ, Nunn AJ, Thompson AJ. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-1526.
71. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007;23:17-24.
72. Rea K, Roche M, Finn DP. Supraspinal modulation of pain by cannabinoids: The role of GABA and glutamate. Br J Pharmacol 2007;152:633-648.
73. Cassan C, Liblau RS. Immune tolerance and control of CNS autoimmunity: From animal models to MS patients. J Neurochem 2007;100:883-892.
74. Skunric DS. Experimental models of relapsin-remitting multiple sclerosis: Current concepts and perspective. Curr Neurovasc Res 2005;2:349-362.
75. Jean-Gilles L, Feng S, Tench CR, Chapman V, Kendall DA, Barrett DA, Constantinescu CS. Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 2009;287:212-215.
76. Centonze D, Bari M, Rossi S, et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007;130:2543-2553.
77. Galiegue S, Mary S, Merchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232:54-61.
78. Achiron A, Miron S, Lavie V, Margalit R, Biegon A. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: Implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 2000;102:26-31.
79. Croxford JL, Miller SD. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55, 212. J Clin Invest 2003;111:1231-1240.
80. Maresz K, Pryce G, Ponmarev ED, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007;13:492-497.
81. Yiangou Y, Facer P, Durrenberger P. COX-2, CB2 and P2X7- immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006;6:12.
82. Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003;126:2191-2202.
83. Marsican G, Moosmann B, Herman H, Lutz B, Behl C. Neuroprotective properties of cannabinoids against oxidative stress: Role of the cannabinoid receptor CB1. J Neurochem 2002;80:448-456.
84. Croxford JL, Pryce G, Jackson SJ, et al. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol 2008;193:120-129.
85. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000;6:67-70.
86. Hoyte L, Barber PA, Buchan AM, Hill MD. The rise and fall of NMDA antagonists for ischemic stroke. Curr Mol Med 2004;4:131-136.
87. Loria F, Petrosino S, Hernangómez M, et al. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol Dis 2010;37:166-176.
88. Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: Therapeutic implications. Trends Mol Med 2002;8:58-61.
89. Hansen HH, Schmid PC, Bittigau P, et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 2001;78:1415-1427.
90. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001;413:527-531.
91. Schmid HH, Schmid PC, Natarajan V. The N-acylation-phosphodiesterase pathway and cell signalling. Chem Phys Lipids 1996;80:133-142.
92. Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HH. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 2004;88:1159-1167.
93. Amantea D, Spagnuolo P, Bari M, et al. Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol. FEBS J 2007;274:4464-4775.
94. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 2003;23:7767-7775.
95. Schabitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S, Piomelli D. Release of fatty acid amides in a patient with hemispheric stroke: A microdialysis study. Stroke 2002;33:2112-2114.
96. Sugiura T, Yoshinaga N, Kondo S, Waku K, Ishima Y. Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxin-administered rat brain. Biochem Biophys Res Commun 2000;271:654-658.
97. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 2004;129:743-750.
98. Jin KL, Mao XO, Goldsmith PC, Greenberg, DA. CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 2000;48:257-261.
99. Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF. Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 2008;152:753-760.
100. Ashton JC, Rahman RM, Nair SM, Sutherland BA, Glass M, Appleton I. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 2007;412:114-117.
101. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999;19:2987-2995.
102. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 2002;22:9771-9775.
103. Alvarez FJ, Lafuente H, Rey-Santano MC, et al. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res 2008;64:653-658.
104. Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, Ganea D, Tuma RF. Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmun Pharmacol 2009;4:249-259.
105. Degn M, Lambertsen KL, Petersen G, et al. Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice. J Neurochem 2007;103:1907-1916.
106. Hansen HH, Azcoitia I, Pons S, et al. Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J Neurochem 2002;82:154-158.
107. 9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res 2000;857:183-187.
108. Mathew RJ, Wilson WH, Davis R. Postural syncope after marijuana: A transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav 2003;75:309-318.
109. Lavie G, Teichner A, Shohami E, Ovadia H, Leker RR. Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia. Brain Res 2001;901:195-201.
110. Durmaz R, Oxden H, Kanbak G, Aral E, Arslan OC, Kartkaya K, Uzuner K. The protective effect of dexanabinol (HU-211) on nitric oxide and cysteine protease-mediated neuronal death in focal cerebral ischemia. Neurochem Res 2008;33:1683-1691.
111. Eshhar N, Striem S, Kohen R, Tirosh O, Biegon A. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur J Pharmacol 1995;283:19-29.
112. Hayakawa K, Mishia K, Nozako M, et al. Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacol 2007;52:1079-1087.
113. Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152:1092-1101.
114. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 2006;103:7895-7900.
115. Köfalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlágh B. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: A combined immunochemical and pharmacological analysis. J Neurochem 2005;25:2874-2884.
116. Fernandez-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 2009;156:1029-1040.
117. Pisani A, Fezza F, Galati S, et al. High endogenous cannabinoid levels in cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol 2005;57:777-779.
118. Garcia-Arencibia M, Garcia C, Kurz A, et al. Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of PARK genes. J Neural Transm 2009;73:269-275.
119. Van Der Stelt M, Veldhuis WB, Maccarrone M, et al. Acute neuronal injury, excitotoxicity and the endocannabinoid system. Mol Neurobiol 2002;26:317-346.
120. Gonzalez S, Scorticati C, Garcia-Arencibia M, de Miguel R, Ramos JA, Fernandez-Ruiz J. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res 2006;1073:209-219.
121. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiol Dis 2005;19:97-107.
122. Maison P, Walker DJ, Walsh FS, Williams G, Doherty P. BDNF regulates neuronal sensitivity to endocannabinoids. Neurosci Lett 2009;467:90-94.
123. De March Z, Zuccato C, Giampá C, et al. Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions. Neuroscience 2008;152:734-740.
124. Palazuelos J, Aguado T, Pazos MR, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009;132:3152-3164.
125. Crews L, Rockenstein E, Marliah E. APP transgenic modeling of Alzheimer's disease: Mechanisms of neurodegeneration and aberrant neurogenesis. Brain Struct Funct 2010;214:111-126.
126. Molero AE, Gokhan S, Gonzalez S, Feig JL, Alexandre LC, Mehler MF. Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. Proc Natl Acad Sci USA 2009;106:21900-21905.
127. Aguado T, Romero E, Monory K, et al. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J Biol Chem 2007;282:23892-23898.
128. Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzmán M, Galve-Roperh I. Non-Psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 2006;20:2405-2407.
129. Goncalves MB, Suetterlin P, Yip P, et al. A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol Cell Neurosci 2008;38:526-536.
130. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. Cannabinoids Delta (9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 2010;285:1616-1626.
131. Correa F, Hernangómez M, Mestre L, et al. Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: Roles of ERK1/2, JNK, and NF-kappaB. Glia 2010;58:135-147.
132. Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L. Cannabidiol: A promising drug for neurodegenerative disorders? CNS Neurosci Ther 2009;15:65-75.
133. Hwang J, Adamson C, Butler D, Janero DR, Makriyannis A, Bahr BA. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality. Life Sci 2010;86:615-623.
134. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 2005;7:625-654.